Sarris J

The need for another tool: Australian healthcare professionals on the use of psilocybin for existential distress in people with cancer.

Adler H, Filipic R, Gonzalez M +8

Europe PMC2026

ArticleDMT

Acute experiences and persisting psychological effects associated with an encapsulated DMT-harmala alkaloid combination: results of a phase 1 study.

Perkins D, Halman A, Urokohara A +7

ArticleDMT

DMT and harmala alkaloids: an exploratory study of oral Acacia based formulations in healthy volunteers.

Bonomo YA, Norman AF, Collins L +4

Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief (PARTING) trial: protocol for an open-label pilot trial for cancer-related bereavement.

Beesley VL, Kennedy TJ, Maccallum F +12

Long-Term Mental Health and Wellbeing Outcomes Associated with Naturalistic Ayahuasca Consumption.

Pagni BA, Halman A, Sarris J +3

Europe PMC2026

ArticleKetamine

Ketamine's Altered States Meta-Analysis: The Relationship Between Psychomimetic and Clinical Effects With Focus in Depression.

Tavares VDO, da Costa Gonçalves KT, de Morais Barros ML +10

Associations Between Ayahuasca Use in Naturalistic Settings and Mental Health and Wellbeing Outcomes: Analysis of a Large Global Dataset.

Perkins D, Sarris J, Cowley-Court T +7

Europe PMC2026

Harnessing Pharmacogenomics in Clinical Research on Psychedelic-Assisted Therapy.

Halman A, Conyers R, Moore C +3

Artificial intelligence and psychedelic medicine.

Sarris J, Halman A, Urokohara A +2

Europe PMC2024

Ayahuasca and Dimethyltryptamine Adverse Events and Toxicity Analysis: A Systematic Thematic Review.

White E, Kennedy T, Ruffell S +2

Europe PMC2024

Drug-drug interactions involving classic psychedelics: A systematic review.

Halman A, Kong G, Sarris J +1

Europe PMC2024

Ayahuasca: A review of historical, pharmacological, and therapeutic aspects.

Ruffell SGD, Crosland-Wood M, Palmer R +13

PreprintPsilocybin

Drug-drug interactions between classic psychedelics and psychoactive drugs: a systematic review

Halman A, Kong G, Sarris J +1

Default Mode Network Modulation by Psychedelics: A Systematic Review.

Gattuso JJ, Perkins D, Ruffell S +11

PreprintAyahuasca

Ayahuasca – a review of historical, pharmacological, and therapeutic aspects

Ruffell S, Netzband N, Tsang W +9

Psychotherapeutic and neurobiological processes associated with ayahuasca: A proposed model and implications for therapeutic use.

Perkins D, Ruffell SGD, Day K +2

Moderators of ayahuasca's biological antidepressant action.

de Sousa GM, de Oliveira Tavares VD, de Menezes Galvão AC +10

Changes in mental health, wellbeing and personality following ayahuasca consumption: Results of a naturalistic longitudinal study.

Perkins D, Pagni BA, Sarris J +2

ArticlePsychedelics

Disruptive innovation in psychiatry.

Sarris J

Psychedelic medicines for mood disorders: current evidence and clinical considerations.

Sarris J, Pinzon Rubiano D, Day K +2

Influence of Context and Setting on the Mental Health and Wellbeing Outcomes of Ayahuasca Drinkers: Results of a Large International Survey.

Perkins D, Schubert V, Simonová H +5

Europe PMC2021

Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm.

Perkins D, Sarris J, Rossell S +17

Europe PMC2021